Publications by authors named "A L Rosenbaum"
Background: The prognosis in patients with advanced cardiac amyloidosis (CA) remains poor.
Objectives: We sought to describe survival post heart transplantation (HT) in amyloid compared with non-amyloid recipients, highlight waitlist times within the new allocation system across three Organ Procurement and Transplantation Network (OPTN) regions, and describe multiorgan transplantation (MOT) in hereditary amyloidosis.
Methods: This is a retrospective review of end-stage CA patients who underwent HT at Mayo Clinic from January 2007 to December 2020.
Background: Although recommended in International Society for Heart and Lung Transplantation (ISHLT) guidelines, transition to mammalian targets of rapamycin (mTOR) inhibitors in heart transplant recipients is not routinely performed, in part due to perceived risk of rejection. This study sought to evaluate the incidence and risk factors for biopsy-proven, clinically relevant rejection following conversion from calcineurin inhibitor (CNI) to sirolimus (SRL) immunosuppression.
Methods: A single center retrospective study was conducted of all consecutive adult patients who underwent orthotopic heart transplantation (OHT) and CNI-free SRL conversion from January 1999 to January 2023.
Ground covers areused inproduce production to enhance plant growth and control diseases and pests. While various factors are considered when selecting commercial ground covers, food safety, particularly the survival of foodborne pathogens, is often overlooked. This study aimed to assess the survival ofSalmonellaon different ground covers, including biodegradable mulch, landscape fabric, and plastic mulch.
View Article and Find Full Text PDFArticle Synopsis
- Malignant glioma, a deadly brain cancer, creates an immunosuppressive environment that limits the effectiveness of treatments targeting the immune system.
- Researchers used single-cell RNA sequencing to identify glioma cells expressing CD83, a marker linked to mature immune cells, and studied its effects on tumor growth and immune response in mice and human samples.
- Findings indicate that CD83+ tumor cells may promote anti-tumor activity by enhancing T cell responses and increasing inflammatory signals, suggesting that CD83 could be a potential target for improving immunotherapy in glioma patients.